WilmerHale advised PTC Therapeutics, while Ropes & Gray advised Blackstone on the deal. Blackstone announced a strategic financing collaboration for up to $1 billion in funding...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised IDRx on the deal. Clinical stage precision cancer biopharmaceutical company IDRx announced licensing transactions with Germany-based Merck KGaA and Blueprint Medicines to...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented EQRx in the transaction. EQRx announced a strategic drug creation, development, and commercialization collaboration with Aurigene Discovery Technologies Limited to develop drug...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Cullinan Oncology in the deal. Cullinan Oncology announced a strategic collaboration with Taiho Pharmaceutical under which Taiho will acquire Cullinan Oncology’s subsidiary Cullinan...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised EQRx in the deal while Wilson Sonsini Goodrich & Rosati represented InSilico. EQRx annlounced a strategic collaboration with Insilico Medicine to jointly...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised ImmunoGen on the deal. ImmunoGen, a leader in the field of antibody-drug conjugates for the treatment of cancer, announced a global, multi-year...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Ovid Therapeutics on the deal. Ovid Therapeutics announced a strategic partnership with U.K.-based Healx, an AI-powered technology company, that granted Healx the...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised EQRx in the deal. EQRx announced a partnership to leverage Germany-based Evotec’s data-driven integrated drug discovery and development platform across different drug...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised EQRx in the deal. EQRx announced a strategic collaboration with Abdul Latif Jameel Health, part of the international diversified family business of...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Verastem Oncology in the deal. Verastem Oncology announced a collaboration to evaluate Mirati Therapeutics’ investigational KRAS inhibitor drug with Verastem’s investigational inhibitor drug...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Ironwood Pharmaceuticals in the collaboration and license option agreement with COUR Pharmaceutical Development Company. The agreement gives Ironwood an option to acquire...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised EQRx on the deal. EQRx announced a strategic drug discovery and development partnership to use Absci’s artificial intelligence and synthetic biology platform...
You must be a Standard 1 Year member to access this content.
